TXG vs. SBRA

In the year-to-date period, TXG achieves a -44.57% return, which is significantly lower than SBRA's 5.36% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for 10x Genomics, Inc. (TXG) and Sabra Health Care REIT, Inc. (SBRA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current TXG Sharpe Ratio is -0.97, which is lower than the SBRA Sharpe Ratio of 1.81. The chart below compares the historical Sharpe Ratios of TXG and SBRA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

TXG has not paid dividends to shareholders, while SBRA's dividend yield for the trailing twelve months is around 6.70%.

The maximum TXG drawdown since its inception was -96.47%, which is greater than SBRA's maximum drawdown of -74.93%. Use the drawdown chart below to compare losses from any high point for TXG and SBRA. For additional features, visit the drawdowns tool.

10x Genomics, Inc. (TXG) has a higher volatility of 29.85% compared to Sabra Health Care REIT, Inc. (SBRA) at 8.03%. This indicates that TXG's price experiences larger fluctuations and is considered to be riskier than SBRA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between 10x Genomics, Inc. and Sabra Health Care REIT, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.